PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2134024
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2134024
IVD Disposables Market size was valued at US$ 8,009.4 Million in 2025, expanding at a CAGR of 6.3% from 2026 to 2033.
IVD disposable is a disposable consumable item that includes such components as microplates, pipette tips, test tubes, and microfluidic cartridges and is meant to be used for in vitro diagnostics. They allow achieving the necessary accuracy and preventing any cross-contamination while conducting analyses of bio-fluids (blood, urine, etc.) and tissues. IVD disposable is a disposable consumable item that includes such components as microplates, pipette tips, test tubes and microfluidic cartridges and is meant to be used for in vitro diagnostics. The main feature of these products consists of the special bio-compatible polymer vessel that allows for the accurate handling of liquid in specially designed wells or micro-channels together with the necessary surface treatment or reagents for the processing of biospecimens. Their reliable design ensures seamless workflow efficiency and high diagnostic accuracy in modern clinical laboratories.
IVD Disposables Market- Market Dynamics
Rising Chronic Disease Burden to Boost Market Growth
The growing cases of chronic conditions like diabetes, heart disease, and cancer are driving the need for early diagnosis and routine monitoring. Continuous requirements of routine tests will result in continuous demands for disposable IVDs, which will further lead to growth in the market. In November 2025, as per the OECD report, more than one-third of people aged 16 and above were suffering from chronic health diseases, which can be termed as long-term health conditions, in 29 OECD countries. Chronic health illnesses are also linked to the income disparity, where 44% of people in the lowest income quintile suffered from chronic illnesses, while 28% of those in the highest income quintile suffered from chronic illnesses, making a difference of 15 percentage points. In addition, according to the OECD, 8.6% of the adult population suffered from diabetes illness, while 82% of the primary care consumers over the age of 45 years suffered from at least one chronic health illness, and 52% had two or more chronic illnesses. Thus, growing needs for chronic care emphasize the significance of IVD disposables.
The Global IVD Disposables Market is segmented on the basis of Product Type, Application, Technology, Testing Setting, and Region.
Based on product type, bottles and vials account for a substantial share in the IVD Disposables market as a result of their extensive use for the storage and transportation of diagnostic reagents and samples in varied operations while maintaining the sterility and chemical stability of tests. In June 2025, Sysmex received certification for a closed-loop recycling system for the collection and recycling of reagent bottles in all parts of the country. The recycling initiative has further underlined the critical importance of bottles and vials in diagnostic applications.
IVD Disposables Market- Geographical Insights
North America holds a key position in the market due to advanced infrastructure of healthcare, use of diagnostic tools, and presence of prominent market participants. For example, during August 2026, based on the report issued by the Government of Canada, the plans of Canada for developing the health and biotechnology data system would assist in doubling the exports from USD 13,000 million to USD 26,000 million .Moreover, as a result of the plan, there would not only be an increase in the number of companies from 900 to 1800 and the high-growth firms from 40 to 80 but also in the equity investments from USD 1,000 million to USD 2,000 million through creating an innovative environment of health care with a lot of technology investments in the clinic. This helps to ensure that North America remains ahead of others through advancements in medical services
The Asia-Pacific region is expected to experience the rapid growth due to the increased investments in the healthcare industry, increased levels of awareness when it comes to prevention, and advanced levels of laboratory facilities. In May 2026, according to the World Health Systems Facts Org, in Japan, deaths that could have been prevented at an individual level have been brought down from 104 deaths per 100,000 people to 86 deaths per 100,000 people. Additionally, 96% of children that were eligible for measles vaccination received two doses of vaccination, and 99% of children were eligible for three doses of vaccinations against diphtheria, tetanus, and pertussis vaccine. Lastly, 45% of women aged 50-69 had mammograms screened. These figures highlight the role of preventive healthcare measures, including vaccination, screening, and early detection, in improving population health outcomes.
Leading firms that are in the IVD disposables industry are looking to gain a competitive advantage through innovative product development and acquisitions. The leading firms like Roche Diagnostics, Abbott Diagnostics, Siemens Healthineers, Thermo Fisher Scientific, and Danaher Corporation are still working on increasing their product capabilities in the IVD disposables industry. In March 2026, Abbott has completed a strategic acquisition of Exact Sciences and is set to combine the respective companies' non-invasive cancer screening and liquid biopsy test product categories. The aim of this strategic acquisition is to increase Abbott's IVD product portfolio through the incorporation of stool DNA sample collection tubes, blood sample collection tubes, and micro-fluidic testing disposables within Abbott's global diagnostic distribution network. These combined efforts underscore how strategic expansion and product innovation continue to propel market growth.
In July 2026, Beckman Coulter Diagnostics, which is a subsidiary company of Danaher, launched an automated urinalysis system named DxU 1800. The system includes urine chemistry reagent strips along with reaction wells and fluidic disposals that are designed specifically. Danaher invested money in the capital expenditure in order to make engineered disposables of in vitro diagnostics (IVD) for high throughput.